The Economic Burden of Prostate Cancer in Antigua and Barbuda: A Prevalence-Based Cost-of-Illness Analysis from the Healthcare Provider Perspective.

In Antigua and Barbuda, prostate cancer is known for its epidemiological burden; however, its economic burden on the healthcare system is unknown. This study aimed to assess the economic burden of prostate cancer in Antigua and Barbuda from the healthcare provider's perspective. To conduct this prevalence-based cost-of-illness study, we used patient data abstracted from records at key study sites for the period of 2017-2021 to establish a yearly prevalence. Top-down and bottom-up approaches were used to estimate the direct medical cost. The cost was computed at the 2021 price level and converted to United States dollars (USD). The total annual direct medical cost for prostate cancer was estimated at USD 1.8 million (ranging between USD 1.4 million and USD 2.3 million). Stages II and III disease accounted for a combined greater share of the cost. The direct medical unit cost for screening, diagnosing, and treating a prostate cancer patient was USD 126,388.98. The top contributors to this cost were surgery (USD 20,913.42), renal complications/renal failure (USD 20,674.86), and hormonal therapy (USD 31,824.00). The results of this study provide evidence of the economic burden of prostate cancer in Antigua and Barbuda. Our findings appear reasonable. Besides contributing to further economic research, they will be useful for policy development, resource allocation, and cost containment measures.